Company / Cash & Equivalents
Beam Therapeutics Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$294.9M
FY2025
5-year range
$232.8M / $560.0M
FY2021-FY2025
Trend
+4.6%
vs FY2024
Sector context
#64 of 207
Health Care
What the data says
At $295M, Beam Therapeutics Inc.'s cash & equivalents ranks #64 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 7 years, ranging from $37M in FY2020 to $560M in FY2021.
Based on SEC 10-K filings.
$295M in FY2025 with a 5-year CAGR of +51.3%.
Declined from $436M to $295M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +8.2%
- 5-Year CAGR
- +51.3%
- 10-Year CAGR
- -
Sector benchmark
#64 of 207 in Health CareTop 31% of 207This company $294.9M Sector average $669.5M
▼
-55.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +51.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 4.6% year-over-year.
- Ranks #64 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $294.9M | +4.6% |
| FY2024 | $282.0M | -35.3% |
| FY2023 | $435.9M | +87.3% |
| FY2022 | $232.8M | -58.4% |
| FY2021 | $560.0M | +1404.5% |
| FY2020 | $37.2M | +0.0% |
| FY2019 | $37.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026